1.The effects of Ginger combined with Rhubarb on hyperuricemia in mice
Chinese Journal of Biochemical Pharmaceutics 2017;37(8):9-10
Objective This study was aimed to investigate the effects of Ginger combined with Rhubarb on hyperuricemia in mice. Methods The mice hyperuricemic model was made by orally administering yeast extract, The mice were randomly divided into 7 groups,includinglow,middle and high dose of Ginger combined with Rhubarb group, Rhubarb group, and allopurinol group was given corresponding drugs respectively by gavage, and the uric acid (uA), creatinine (Cr), urea nitrogen (BUN) level in blood and XOD activity in liver were observed for all mice in each group. Results Compared to hyperuricaemia model control group,UA level and XOD activity in liver of mice of the three doses of Ginger combined with Rhubarb groups received dose-dependent decrease. Conclusion Ginger combined with Rhubarb can reduce UA level and XOD activity in liver in hyperuricaemia mice model.
2.Efficacy of different administration methods for labor analgesia
Huihui LI ; Lifang ZHAO ; Jiefang FAN
Chinese Journal of Primary Medicine and Pharmacy 2024;31(2):239-242
Objective:To investigate the clinical efficacy of different administration methods for labor analgesia.Methods:This randomized controlled study was conducted on 152 parturient women who underwent vaginal delivery at the Xinxiang Central Hospital from February to June 2023. These women were divided into a control group and an observation group, with 76 women per group. Women in the control group received 3 mL of 0.1% ropivacaine hydrochloride after routine epidural catheterization, followed by 3 mL of analgesic drugs after 3 minutes. For those without any special reactions, an analgesic pump containing 9 mL of medication was used after 3 minutes until the end of labor. In the observation group, 3 mL of 0.1% ropivacaine hydrochloride was administered as a trial dose before the epidural catheter was inserted into the epidural space. After 3 minutes, the postpartum woman lay flat and was given another 3 mL of analgesic pump medication. After 3 additional minutes, an additional 9 mL of the medication was administered. The analgesic pump was connected and turned on until the catheter was removed after delivery. The epidural catheter failure rate was assessed in each group. Before epidural puncture (T 1), within 30 minutes after the onset of anesthesia (T 2), and at the time of full dilation of the cervix (T 3), Visual Analogue Scale scores, the number of patient attempts to additionally use an analgesia pump, maternal satisfaction, the number of cases requiring cesarean section conversion, the incidence of adverse reactions (such as nausea, vomiting, and fever), and Apgar scores for newborns were recorded in each group. Results:The epidural catheter failure rate in the observation group was 1.3% (1/76), which was significantly lower than 10.5% (8/76) in the control group ( χ2 = 5.79, P < 0.05). At T 2 and T 3, the Visual Analogue Scale score in the observation group was (0.89 ± 0.08) points and (2.1 ± 0.07) points, respectively, which were significantly lower than (2.55 ± 0.07) points and (3.35 ± 0.07) points in the control group ( t = 238.54, 133.17, both P < 0.001). The number of patient attempts to additionally use an analgesia pump in the observation group was (1.00 ± 0.84) counts, which was significantly less than (4.00 ± 0.65) counts in the control group ( t = 29.47, P < 0.001). Maternal satisfaction in the observation group was 100% (76/76), which was significantly higher than 92.1% (70/76) in the control group ( χ2 = 6.25, P < 0.05). The number of cases requiring cesarean section conversion in the observation group was 0 (0/76), which was significantly lower than 52.6% (4/76) in the control group ( χ2 = 4.10, P < 0.05). Conclusion:Administering a trial dose (3 mL) of 0.1% ropivacaine hydrochloride before placing the epidural catheter during labor analgesia can greatly increase the placement success rate of the catheter and enhance pain relief effectiveness. This has a certain clinical application value.